Publicaciones en colaboración con investigadores/as de Seoul National University Hospital (9)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Advances in Therapy, Vol. 41, Núm. 11, pp. 4125-4139

2023

  1. Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases

    HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216

  2. Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases

    HEPATOBILIARY SURGERY AND NUTRITION, Vol. 12, Núm. 2, pp. 205-216

2021

  1. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2016

  1. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

    The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

2015

  1. Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

    Expert Review of Anticancer Therapy, Vol. 15, Núm. 7, pp. 737-748

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206